dr. tagawa on brca2 in patients with prostate cancer receiving psma-targeted radionuclide therapy
Published 5 years ago • 455 plays • Length 2:29Download video MP4
Download video MP3
Similar videos
-
1:51
dr. tagawa on remaining questions with psma-targeted radionuclide therapy in mcrpc
-
1:49
dr. tagawa on preliminary data with 225ac-j591 in mcrpc
-
1:18
dr. tagawa discusses radiotherapy in prostate cancer
-
1:18
dr. gomella discusses role of brca1/2 in prostate cancer
-
1:32
dr. tagawa on next steps for taxanes in prostate cancer
-
0:49
how the breast cancer gene also impacts risk for prostate cancer
-
9:02
chemotherapy for brca-mutated prostate cancer
-
1:50
brca2 gene implicated in rare but lethal prostate cancer
-
2:06
dr. tagawa on ctc in neuroendocrine-positive prostate cancer
-
1:32
dr. chang discusses the use of parp inhibitors in prostate cancer
-
10:15
brca2, prostate cancer lynparza
-
6:32
metastatic prostate cancer: testing for brca mutations
-
2:31
dr. tagawa on abiraterone and docetaxel in mcrpc
-
12:07
parp inhibitors in brca1/2-mutated patients in prostate cancer
-
1:12
scott tagawa, md, on the study investigating nadofaragene firadenovec in bcg unresponsive nmibc
-
2:04
a phase ii trial investigating neoadjuvant abiraterone and cabazitaxel in high-risk prostate cancer
-
1:24
dr. ledermann on response to rucaparib in recurrent ovarian cancer
-
2:14
dr. tagawa discusses darolutamide in crpc
-
4:30
profound: olaparib for hrr mcrpc